What Is the Clinical Impact of the Genetic Polymorphism Observed with the Effectiveness of some P2Y12 Inhibitors?

August 3, 2021

Moderator:W. Brian Gibler, MD FACEP, FACC, FAHA
Other Participants: Deepak L. Bhatt, MD, MPH and Natalie Kreitzer, MD, MS

Role of genetic polymorphism in TIA and stroke is and has been controversial, since the initial introduction of clopidogrel. Hear Drs. Bhatt and Kreitzer discuss the basics and background associated with the metabolism of the various agents, where we have come, the management of ACSand also for acute ischemic stroke, the role of dual antiplatelet therapy (DAPT), pivotal trials such as THALES, PIVOT, and THEMIS, and the importance of closely monitoring for a recurrent stroke, which happens with high frequency within the 1st month post a stroke.

Please login or register to post comments.
More Entries